Table 2 The association between continuity use of lipid-lowering therapy and GI cancer

 non-user

Ref

–

–

 MPR < 25%

1.029

0.835

1.268

 MPR < 50%

0.741

0.574

0.958

 MPR < 75%

0.636

0.480

0.842

 MPR ≥ 75%

0.438

0.305

0.629

 Aspirin

0.995

0.991

0.998

 Metformin

0.996

0.980

1.012

 Community health center

0.752

0.468

1.209

 clinic

0.711

0.506

0.999

 Hospital

0.868

0.573

1.314

 General hospital

0.766

0.523

1.121

 Tertiary hospital

Ref

–

–

CCI

1.193

1.127

1.263

 Male

1.874

1.582

2.219

 Female

Ref

–

–

 30–44

Ref

–

–

 45–59

2.612

1.906

3.579

 60–75

5.656

4.000

7.998

  < 18.5

1.009

0.496

2.051

 18.5–22.9

Ref

–

–

 23–24.9

1.036

0.844

1.272

 25–29.9

0.888

0.723

1.091

 ≥ 30

0.953

0.578

1.571

 Capital area

1.121

0.924

1.360

 Metropolitan

0.937

0.749

1.172

 Other

Ref

–

–

 Low

1.085

0.857

1.373

 Low-moderate

1.049

0.838

1.313

 Moderate-high

1.073

0.856

1.344

 High

Ref

–

–

 Medicaid

1.410

0.832

2.391

 Self-Employed

1.107

0.932

1.315

 Employees

Ref

–

–

 2004–2007

Ref

–

–

 2008–2011

0.688

0.556

0.851

 2012–2015

0.631

0.458

0.867